© 2022 accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy
THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
The OMICs-guided biomarker profiling performed in COVend will provide a profound understanding of the interplay between the systemic inflammation of the endothelium caused by SARS-CoV-2 infection and the – also systemic – action mode FX06. Recent publications demonstrate the effectiveness of OMICs technologies (including proteomics, metabolomics and lipidomics) in the research on COVID-19, emphasising the tremendous changes and complexity on the molecular level in infected patients.
Primary human pulmonary endothelial cells and an endothelial cell line will be incubated in the presence or absence of FX06. The inflammatory/immunological activation status of ECs will be tested in flow cytometric analyses and the ECs will also be investigated under shear stress conditions.
COVend’s initial modelling approach is based on automated characterisation of the study cohort using advanced unsupervised clustering methods. A wide variety of data sources will be integrated such as OMICs, vital signs, and open registry data. After patient characterisation analysis, a more directed supervised and semi-supervised approach will be used to train specific machine learning models for a discrete decision support target.
The clinical trial is at the heart of the work in COVend, to deliver FX06 as a viable therapy against COVID-19. This studies ensures that our medical research is effective and safe, and relies entirely on patients and healthy volunteers. Learn more about COVend’s clinical trial.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]
© 2022 accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy